|
A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Athenex; Merck Sharp & Dohme |
|
|
|
Stock and Other Ownership Interests - Athenex; DemeRx |
Patents, Royalties, Other Intellectual Property - Athenex |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Athenex |
Travel, Accommodations, Expenses - Athenex |
|
|
No Relationships to Disclose |
|
|
Employment - Zenith Technology |
Leadership - Zenith Technology |
Stock and Other Ownership Interests - Zenith Technology |
|
|
Consulting or Advisory Role - Bayer; Community First Health Plans; New B Innovation |
Travel, Accommodations, Expenses - Bayer; New B Innovation |